Why Wegovy (Semaglutide 2.4 mg) Causes Injection Site Reactions: The Mechanism Explained

How often do Wegovy injection site reactions happen?

The Wegovy label pools three placebo-controlled weight-management trials: 2,116 adults on semaglutide 2.4 mg once weekly and 1,261 on placebo, treated for up to 68 weeks. Injection site reactions were reported by 1.4% of patients on Wegovy and 1% on placebo [1].

Gastrointestinal effects were far more common in the same trials, with nausea in 44% versus 16% and diarrhea in 30% versus 16% [1].

What does the label warn about beyond the injection site?

The Wegovy label's hypersensitivity warning says anaphylactic reactions and angioedema have been reported after marketing, and that Wegovy should be discontinued if a hypersensitivity reaction is suspected [1]. A prior serious hypersensitivity reaction to semaglutide or to any excipient in Wegovy is a contraindication [1].

The label also reports that allergic reactions occurred in 16% of patients who developed anti-semaglutide antibodies, compared with 7% of those who did not [1].

Is it the needle, the drug, or the liquid?

A 2.4 mg Wegovy dose is delivered as 0.75 mL of solution under the skin [2]. Beyond that, we found no published study that measured which part of the injection drives a local reaction: the needle, the volume of fluid, the preservatives and buffer in the pen, or an immune response to semaglutide itself.

Does the injection site matter?

The label says to inject Wegovy subcutaneously in the abdomen, thigh, or upper arm, and that the injection site can be changed without a dosage adjustment [1]. Semaglutide exposure is similar whether the dose goes into the abdomen, thigh or upper arm [1]. The label does not say whether changing sites reduces injection site reactions.

Burning or sensitive skin: is that an injection site reaction?

The label tracks dysesthesia, meaning altered skin sensation such as burning, pain from touch or sensitive skin, as its own adverse reaction separate from injection site reactions, and says the rate rises with dose [1]. In the two 72-week trials comparing 7.2 mg with 2.4 mg and placebo, dysesthesia was reported by 22% on 7.2 mg, 6% on 2.4 mg and 0% on placebo, and 18% of those affected on 7.2 mg had not recovered by the end of the trial [1].